Zorz Alessandra, Morzenti Sabrina, Bianchi Claudia, Campanaro Federica, Monte Francesca De, Ponti Elena De, Berti Sara, Erba Paola Anna, Guerra Luca, Poli Gian Luca
Medical Physics Department, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata 64, 35128 Padua, Italy.
Medical Physics Department, Fondazione IRCCS San Gerardo dei Tintori, Via Pergolesi 33, 20900 Monza, Italy.
Phys Med. 2025 May;133:104984. doi: 10.1016/j.ejmp.2025.104984. Epub 2025 Apr 23.
Diagnostic Reference Levels (DRLs) are essential for optimizing patient protection in radiological imaging. PET/CT acquisitions are fundamental in modern nuclear medicine for diagnosis, staging and tumor response evaluation. The hybrid nature of PET/CT results in a total dose to the patient from both modalities. Therefore, it is appropriate to set and evaluate DRLs independently for each modality. While DRLs for some PET tracers are extensively described by various national and international guidelines, similarly established guidelines for the low-dose CT component are lacking.
In 2022, a multicenter collaboration was established among three Italian Hospitals to evaluate dosimetric indices for almost 13,000 PET/CT scans using various scanner technologies and tracers. The dosimetric data were classified based on the radiopharmaceuticals injected and further stratified according to scan length: Whole Body (WB), head vertex-to-feet and brain.
The results for all tracers and imaging procedures evaluated are compliant with or lower than available DRLs. For some exam types, national DRLs are not currently defined and so typical values, calculated as the median of the data distribution in this study, are proposed. For the PET the typical values are proposed in terms of total and per kilogram administered activity, while for the CT they are proposed in terms of CTDI and DLP.
In line with Directive 2013/29/Euratom, these collected data could be valuable for a future review of DRLs for both PET tracers and low-dose CT component in WB studies, and for defining new DRLs for low-dose CT component in vertex-to-feet and brain studies.
诊断参考水平(DRLs)对于优化放射成像中的患者防护至关重要。PET/CT采集在现代核医学中对于诊断、分期和肿瘤反应评估具有基础性作用。PET/CT的混合特性导致患者从两种模式中接受的总剂量。因此,为每种模式独立设定和评估DRLs是合适的。虽然各种国家和国际指南广泛描述了某些PET示踪剂的DRLs,但缺乏针对低剂量CT组件的类似既定指南。
2022年,意大利三家医院建立了多中心合作,以评估使用各种扫描仪技术和示踪剂的近13000例PET/CT扫描的剂量学指标。剂量学数据根据注入的放射性药物进行分类,并根据扫描长度进一步分层:全身(WB)、头顶至足部和脑部。
所有评估的示踪剂和成像程序的结果均符合或低于可用的DRLs。对于某些检查类型,目前尚未定义国家DRLs,因此提出了以本研究中数据分布的中位数计算的典型值。对于PET,典型值以总给药活度和每千克给药活度表示,而对于CT,典型值以CTDI和DLP表示。
根据2013/29/Euratom指令,这些收集的数据对于未来审查WB研究中PET示踪剂和低剂量CT组件的DRLs以及确定头顶至足部和脑部研究中低剂量CT组件的新DRLs可能具有价值。